Market Closed -
Nyse
04:00:02 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
0.5285
USD
|
-5.51%
|
|
-20.06%
|
-68.73%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
12,355
|
2,856
|
3,334
|
1,169
|
-
|
-
|
Enterprise Value (EV)
1 |
10,827
|
1,540
|
2,390
|
558.3
|
604
|
570.5
|
P/E ratio
|
-6.16
x
|
-1.35
x
|
-3.67
x
|
-1.84
x
|
-2.35
x
|
-3.87
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
39.4
x
|
5.98
x
|
13.3
x
|
6.07
x
|
4.64
x
|
3.52
x
|
EV / Revenue
|
34.5
x
|
3.22
x
|
9.5
x
|
2.9
x
|
2.4
x
|
1.72
x
|
EV / EBITDA
|
-102
x
|
-8.91
x
|
-6.72
x
|
-1.45
x
|
-2.59
x
|
-6.3
x
|
EV / FCF
|
-34,887,787
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
7.51
x
|
1.84
x
|
3.08
x
|
1.6
x
|
1.65
x
|
1.76
x
|
Nbr of stocks (in thousands)
|
1,486,734
|
1,689,647
|
1,972,725
|
2,211,278
|
-
|
-
|
Reference price
2 |
8.310
|
1.690
|
1.690
|
0.5285
|
0.5285
|
0.5285
|
Announcement Date
|
3/28/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
313.8
|
477.7
|
251.5
|
192.6
|
251.9
|
331.8
|
EBITDA
1 |
-
|
-106
|
-172.8
|
-355.4
|
-384.2
|
-233.2
|
-90.5
|
EBIT
1 |
-
|
-1,828
|
-2,209
|
-864.4
|
-612.7
|
-430.1
|
-318.2
|
Operating Margin
|
-
|
-582.62%
|
-462.41%
|
-343.76%
|
-318.18%
|
-170.72%
|
-95.91%
|
Earnings before Tax (EBT)
1 |
-
|
-1,838
|
-2,121
|
-892.9
|
-578.5
|
-422.1
|
-324.9
|
Net income
1 |
-126.6
|
-1,830
|
-2,105
|
-892.9
|
-578.9
|
-421.4
|
-282.3
|
Net margin
|
-
|
-583.12%
|
-440.63%
|
-355.08%
|
-300.64%
|
-167.25%
|
-85.09%
|
EPS
2 |
-16.18
|
-1.350
|
-1.250
|
-0.4600
|
-0.2875
|
-0.2250
|
-0.1367
|
Free Cash Flow
|
-
|
-310.3
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-98.89%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/14/21
|
3/28/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
148.5
|
168.4
|
144.6
|
66.4
|
98.28
|
80.7
|
80.57
|
55.43
|
34.76
|
37.94
|
46.49
|
51.29
|
57.1
|
59.01
|
71.67
|
EBITDA
1 |
0.562
|
-1.951
|
-23.32
|
-69.63
|
-80.2
|
-100
|
-75.46
|
-83.82
|
-95.77
|
-100.1
|
-79.34
|
-67.23
|
-54.4
|
-74.03
|
-66.13
|
EBIT
1 |
-1,685
|
-674.5
|
-646.9
|
-653
|
-234.5
|
-215.7
|
-184.2
|
-286.4
|
-178.1
|
-178
|
-163.4
|
-151.2
|
-138.6
|
-135.7
|
-138.6
|
Operating Margin
|
-1,134.55%
|
-400.53%
|
-447.32%
|
-983.49%
|
-238.6%
|
-267.34%
|
-228.57%
|
-516.68%
|
-512.49%
|
-469.12%
|
-351.38%
|
-294.77%
|
-242.68%
|
-230.02%
|
-193.4%
|
Earnings before Tax (EBT)
1 |
-1,606
|
-592.8
|
-670.6
|
-669.1
|
-188.9
|
-204.9
|
-173.2
|
-302.9
|
-211.9
|
-165.9
|
-167.4
|
-166.6
|
-164.9
|
-154
|
-148.3
|
Net income
1 |
-1,601
|
-590.5
|
-668.8
|
-669.1
|
-176.5
|
-205
|
-173.3
|
-302.9
|
-211.7
|
-165.9
|
-142.3
|
-121.7
|
-110.2
|
-153.8
|
-148.1
|
Net margin
|
-1,077.93%
|
-350.65%
|
-462.48%
|
-1,007.64%
|
-179.62%
|
-253.98%
|
-215.12%
|
-546.44%
|
-609.1%
|
-437.25%
|
-306.02%
|
-237.3%
|
-193.05%
|
-260.64%
|
-206.65%
|
EPS
2 |
-1.050
|
-0.3700
|
-0.4100
|
-0.4100
|
-0.1000
|
-0.1100
|
-0.0900
|
-0.1600
|
-0.1100
|
-0.0800
|
-0.0780
|
-0.0700
|
-0.0600
|
-0.0725
|
-0.0667
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/22
|
5/16/22
|
8/15/22
|
11/14/22
|
3/1/23
|
5/10/23
|
8/9/23
|
11/8/23
|
2/29/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
1,528
|
1,316
|
944
|
610
|
565
|
598
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-310
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-186%
|
-130%
|
-63%
|
-61.7%
|
-47.9%
|
-19.5%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
1.110
|
0.9200
|
0.5500
|
0.3300
|
0.3200
|
0.3000
|
Cash Flow per Share
2 |
-
|
-0.1900
|
-0.1400
|
-0.1500
|
-0.1800
|
-0.1000
|
-
|
Capex
|
-
|
56.5
|
52.3
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
18.01%
|
10.94%
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/14/21
|
3/28/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
0.5285
USD Average target price
1.62
USD Spread / Average Target +206.53% Consensus |
1st Jan change
|
Capi.
|
---|
| -68.73% | 1.17B | | +43.36% | 54.64B | | -5.31% | 39.92B | | +37.52% | 38.82B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +0.04% | 12.16B | | +25.12% | 12.21B | | +26.04% | 11.94B |
Other Biotechnology & Medical Research
|